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background
 
Sensitization of leukemic cells with hematopoietic growth factors may enhance the cy-
totoxicity of chemotherapy in acute myeloid leukemia (AML).
 
methods
 
In a multicenter randomized trial, we assigned patients (age range, 18 to 60 years) with
newly diagnosed AML to receive cytarabine plus idarubicin (cycle 1) and cytarabine plus
amsacrin (cycle 2) with granulocyte colony-stimulating factor (G-CSF) (321 patients)
or without G-CSF (319). G-CSF was given concurrently with chemotherapy only. Idaru-
bicin and amsacrin were given at the end of a cycle to allow the cell-cycle-dependent cy-
totoxicity of cytarabine in the context of G-CSF to have a greater effect. The effect of
G-CSF on disease-free survival was assessed in all patients and in cytogenetically dis-
tinct prognostic subgroups.
 
results
 
After induction chemotherapy, the rates of response were not significantly different in
the two groups. After a median follow-up of 55 months, patients in complete remission
after induction chemotherapy plus G-CSF had a higher rate of disease-free survival than
patients who did not receive G-CSF (42 percent vs. 33 percent at four years, P=0.02),
owing to a reduced probability of relapse (relative risk, 0.77; 95 percent confidence in-
terval, 0.61 to 0.99; P=0.04). G-CSF did not significantly improve overall survival (P=
0.16). Although G-CSF did not improve the outcome in the subgroup with an unfavor-
able prognosis, the 72 percent of patients with standard-risk AML benefited from G-CSF
therapy (overall survival at four years, 45 percent, as compared with 35 percent in the
group that did not receive G-CSF [relative risk of death, 0.75; 95 percent confidence inter-
val, 0.59 to 0.95; P=0.02]; disease-free survival, 45 percent vs. 33 percent [relative risk,
0.70]; 95 percent confidence interval, 0.55 to 0.90; P=0.006).
 
conclusions
 
Sensitization of leukemic cells with growth factors is a clinically applicable means of
enhancing the efficacy of chemotherapy in patients with AML.
abstract
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revention of relapse remains a
 
challenge in the treatment of acute myeloid
leukemia (AML).
 
1
 
 The high rate of recur-
rence is due to the reemergence of leukemia from
small numbers of residual cells that have escaped
the cytotoxic effect of chemotherapy.
Hematopoietic growth factors stimulate AML
cells in culture, activating metabolic processes and
the cell cycle. In vitro, the simultaneous exposure of
leukemic cells to chemotherapy and growth factors
such as granulocyte–macrophage colony-stimulat-
ing factor (GM-CSF), granulocyte colony-stimulat-
ing factor (G-CSF), and interleukin-3, referred to as
growth-factor priming, increases the susceptibility
of the cells to killing by chemotherapy, especially by
the cell-cycle–specific agent cytarabine.
 
2-11
 
 These
observations suggest a novel therapeutic strategy
for AML, but the value of such an approach has not
been assessed clinically.
In previous trials of AML, G-CSF and GM-CSF
have been widely used after chemotherapy to accel-
erate myeloid regeneration,
 
12-14
 
 but there is infor-
mation only from uncontrolled studies
 
15-17
 
 and
small, randomized studies
 
18-21
 
 about their use in
growth-factor priming. We conducted a random-
ized trial to determine whether G-CSF given only
during the first two induction cycles with cytara-
bine plus idarubicin and cytarabine plus amsacrin
improves disease-free survival in adults with newly
diagnosed AML by increasing the rate of complete
response, reducing the relapse rate, or both. G-CSF
was not given during the aplastic phase after chemo-
therapy. To avoid interference of the second chemo-
therapeutic agent with the cell-cycle–dependent
synergy between cytarabine and G-CSF, idarubicin
(first cycle) and amsacrin (second cycle) were given
at the end of the cycles.
 
patients
 
Previously untreated patients with a confirmed diag-
nosis of AML who were 18 to 60 years of age were
eligible for the study. All subtypes of AML were in-
cluded, except acute promyelocytic leukemia and
blast crisis of chronic myeloid leukemia. Patients
with another active cancer were not eligible, nor
were patients with severe heart, lung, or neurologic
disease. All patients were screened for eligibility be-
fore undergoing randomization.
The study was approved by the ethics committees
of the participating institutions and was conducted
in accordance with the Declaration of Helsinki. All
participants gave their informed consent.
 
risk classification
 
At diagnosis, samples of bone marrow and blood
were examined for cytogenetic abnormalities with
the use of standard banding techniques and classi-
fied according to the International System for Hu-
man Cytogenetic Nomenclature.
 
22
 
 On the basis of
the chromosomal analysis, patients were classified
into three distinct prognostic categories: favor-
able risk, unfavorable risk, and standard risk.
 
23-25
 
Favorable risk was defined by the presence of
t(8;21)(q22;22), inv16(p13q22), or t(16;16)(p13q22)
and a white-cell count of less than 20¬10
 
3
 
 per cubic
millimeter at diagnosis.
 
25
 
 Unfavorable risk was de-
fined by the presence of complex cytogenetic ab-
normalities (defined as at least four unrelated cy-
togenetic clones), monosomies, or deletions of
chromosome 5 or 7 (5q–, 7q–, –5, or –7), abnormal-
ities of the long arm of chromosome 3(q21;q26),
t(6;9)(p23;q34), or abnormalities involving the long
arm of chromosome 11(11q23). Leukemias that had
occurred after chemotherapy or radiotherapy for a
nonhematologic condition and leukemias that had
occurred more than six months after a hematologic
condition (secondary leukemias) were included in
the unfavorable prognostic category. Patients who
did not meet the criteria for favorable or unfavorable
risk were classified as being at standard risk.
 
study design and chemotherapy
 
Patients were enrolled and randomly assigned to re-
ceive G-CSF or no G-CSF during remission-induc-
p
methods
 
Figure 1. Treatment Regimens.
 
Patients were randomly assigned to receive two cycles of induction chemo-
therapy alone or with the addition of granulocyte colony-stimulating factor 
(G-CSF) beginning one day before the start of chemotherapy (day 0) through 
the last day of chemotherapy.
Induction Cycle 1
R
an
do
m
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n
Induction Cycle 2
Idarubicin, 12 mg/m2, days 6, 7, 8
Cytarabine, 200 mg/m2, days 1–7
Amsacrin, 120 mg/m2, days 4–6
Cytarabine, 1000 mg/m2 every 12 hr,
days 1–6
Idarubicin, 12 mg/m2, days 6, 7, 8
Cytarabine, 200 mg/m2, days 1–7
G-CSF, 150 µg/m2, days 0–8
Amsacrin, 120 mg/m2, days 4–6
Cytarabine, 1000 mg/m2 every 12 hr,
days 1–6
G-CSF, 150 µg/m2, days 0–6
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tion cycles 1 and 2 (Fig. 1). Cycle 1 consisted of cy-
tarabine (200 mg per square meter of body-surface
area given by continuous infusion on days 1 through
7) and idarubicin (12 mg per square meter given in-
travenously over a period of 5 to 10 minutes on
days 6, 7, and 8). Cycle 2 consisted of cytarabine
(1000 mg per square meter given intravenously over
a period of 2 hours every 12 hours on days 1 through
6) and amsacrin (120 mg per square meter given
intravenously over a 60-minute period on days 4, 5,
and 6). G-CSF (lenograstim, Aventis) was given sub-
cutaneously or intravenously in a dose of 150 µg per
square meter per day beginning one day before che-
motherapy (day 0) and continuing until the last day
of cycles 1 and 2. The administration of G-CSF was
postponed or interrupted in the event of leukocyto-
sis (more than 30¬10
 
3
 
 leukocytes per cubic milli-
meter) until the white-cell count was below 20¬10
 
3
 
per cubic millimeter. Patients with standard-risk or
unfavorable-risk AML who were in complete remis-
sion after cycle 2 were randomly assigned to a third
cycle of chemotherapy with etoposide and mitoxan-
trone or high-dose chemotherapy with busulfan and
cyclophosphamide followed by autologous stem-
cell transplantation. Allogeneic stem-cell transplan-
tation was performed if a suitable donor was avail-
able and the patient was younger than 55 years of
age. Patients with a favorable cytogenetic profile
were also to receive the third cycle of chemotherapy
with etoposide and mitoxantrone.
 
statistical analysis
 
The primary objective of the study was to determine
the effect of adding G-CSF to induction chemother-
apy on the rate of response, disease-free survival, re-
lapse-free survival, and overall survival. A secondary
objective was to assess the relation between the
defined prognostic subgroups and the outcome.
A complete response was defined by cellular mar-
row with less than 5 percent blasts, no Auer rods, no
evidence of extramedullary leukemia, and peripher-
al granulocyte and platelet counts of at least 1.0¬10
 
3
 
per cubic millimeter and 100¬10
 
3
 
 per cubic milli-
meter, respectively. The time to hematopoietic re-
covery after both cycles 1 and 2 was measured from
the first day of chemotherapy. Disease-free survival
was measured from the time of the first complete
remission to the date of relapse or death from any
cause. Relapse was defined as a recurrence of leu-
kemia after a first complete remission. Event-free
survival was measured from the date of randomiza-
tion to the date of failure to enter a complete remis-
 
* There were no significant differences between the groups. Adequate cytoge-
netic data were obtained in 87 percent of patients. Because of rounding, per-
centages may not total 100. G-CSF denotes granulocyte colony-stimulating 
factor.
† Higher scores on the World Health Organization (WHO) scale indicate poorer 
performance status.
‡ Favorable risk was defined by the presence of t(8;21)(q22;22), inv16(p13q22), 
or t(16;16)(p13q22) and a white-cell count of less than 20¬10
 
3
 
 per cubic milli-
meter at diagnosis.
 
25
 
 Unfavorable risk was defined by the presence of complex 
cytogenetic abnormalities (defined as at least four unrelated cytogenetic 
clones), monosomies, or deletions of chromosome 5 or 7 (5q–, 7q–, –5, 
or –7), abnormalities of the long arm of chromosome 3(q21;q26), t(6;9)(p23;
q34), or abnormalities involving the long arm of chromosome 11(11q23). Leu-
kemias that had occurred after chemotherapy or radiotherapy for a nonhema-
tologic condition and leukemias that had occurred more than six months after 
a hematologic condition (secondary leukemias) were included in the unfavor-
able prognostic category. Patients who did not meet the criteria for favorable 
 
or unfavorable risk were classified as being at standard risk.
 
Table 1. Characteristics of the Patients with Acute Myeloid Leukemia (AML).*
Characteristic
Chemotherapy
(N=319)
Chemotherapy
plus G-CSF
(N=321)
 
Male sex (%) 50.8 50.8
Age
Median (yr)
<35 yr (%)
35–50 yr (%)
≥50 yr (%)
44.9
25.4
36.4
38.2
44.0
30.8
34.9
34.3
White-cell count at diagnosis
Median (¬10
 
¡3
 
/mm
 
3
 
)
Range (¬10
 
¡3
 
/mm
 
3
 
)
≤20¬10
 
3
 
/mm
 
3
 
 (%)
15.9
0.4–446
53.3
16.6
0.3–368
51.7
French–American–British classification (%)
M0
M1
M2
M4
M5
M6
M7
Mx
4.4
16.6
32.6
20.4
17.2
4.1
0.9
3.8
5.3
16.2
26.8
23.1
22.1
5.3
0.6
0.6
WHO performance score (%)†
0
1
2
3 or 4
Unknown
42.0
43.3
11.0
1.6
2.2
38.9
48.0
9.7
2.2
1.2
Secondary leukemia (%) 5.3 7.2
Extramedullary AML (%) 12.0 15.3
Prognostic risk category (%)‡
Favorable
Standard
Unfavorable
7.5
73.4
19.1
5.3
71.7
23.1
Postinduction therapy (%)
Chemotherapy
Autologous stem-cell transplantation
Allogeneic stem-cell transplantation
31.0
16.3
17.9
28.0
15.6
17.1
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sion (set as day 1), death, or relapse, whichever came
first. Overall survival was measured from the date
of randomization.
Random assignments were balanced with use of
a minimization procedure with the hospital as a
stratification factor. We planned to enroll 600 pa-
tients over a period of five years, with an additional
follow-up of two years after the enrollment of the
last patient. This number of patients would give the
study a power of 78 percent to show an absolute in-
crease of 10 percent in the rate of complete remis-
sion (from 70 percent to 80 percent) with the use of
G-CSF; a power of 75 percent to show an absolute
increase of 10 percent in the overall survival rate
(from 35 percent to 45 percent) at three years, giv-
en a relative risk of death of 0.76 and with 375 ex-
pected deaths; and a power of 81 percent to show
an absolute increase of 10 percent in long-term
event-free survival (from 25 percent to 35 percent)
at three years, given a relative risk of 0.76 and 423
expected events, with the use of two-sided tests and
a 5 percent significance level. Within 3.5 years, 655
 
* Plus–minus values are the actuarial means ±SE. Relative risks and 95 percent confidence intervals (CIs) are based on Cox 
regression analysis. Data on patients with a favorable risk (24 in the G-CSF group and 17 in the no–G-CSF group) and pa-
tients with an unfavorable risk (61 and 74, respectively) are not presented, but analyses of these groups showed no sig-
 
nificant differences.
 
Table 2. Effect of Granulocyte Colony-Stimulating Factor (G-CSF) on the Outcome of Acute Myeloid Leukemia (AML) 
at Four Years.*
Outcome No G-CSF (N=319) G-CSF (N=321)
P
Value
Relative Risk of Event
(95% CI)
 
No. of
Events
Probability
of Outcome
at 4 yr
No. of
Events
Probability
of Outcome
at 4 yr
 
% %
 
All patients
 
Overall survival 207 35±3 190 40±3 0.16 0.87 (0.72–1.06)
Event-free survival 228 28±3 215 33±3 0.17 0.88 (0.73–1.06)
Complete remission 265 83±2 255 79±2 0.24
Disease-free survival after 1st complete 
remission
174 33±3 149 42±3 0.02 0.77 (0.62–0.96)
Relapse after 1st complete remission 139 54±3 120 46±3 0.04 0.77 (0.61–0.99)
Death in 1st complete remission 35 13±2 29 11±2 0.29 0.77 (0.47–1.27)
 
No G-CSF (N=234) G-CSF (N=230)
 
No. of
Events
Probability
of Outcome
at 4 yr
No. of
Events
Probability
of Outcome
at 4 yr
 
% %
 
Patients with standard-risk AML
 
Overall survival 155 35±3 128 45±3 0.02 0.75 (0.59–0.95)
Event-free survival 168 29±3 140 39±3 0.01 0.75 (0.60–0.93)
Complete remission 202 86±2 201 87±2
Disease-free survival after 1st com-
plete remission
136 33±3 111 45±3 0.006 0.70 (0.55–0.90)
Relapse after 1st complete remission 105 52±3 89 44±3 0.02 0.72 (0.54–0.96)
Death in 1st complete remission 31 14±2 22 11±2 0.11 0.64 (0.37–1.10)
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patients had been recruited, 640 of whom could be
evaluated. As of August 2002, 445 events had oc-
curred, as defined with respect to event-free surviv-
al, and 407 patients had died.
All analyses were conducted according to the in-
tention-to-treat principle, but 14 ineligible patients
(7 in each group) were excluded, as was 1 who was
lost to follow-up on day 3 and whose data could
therefore not be evaluated. Reasons for ineligibility
were an incorrect diagnosis (lymphoid neoplasia)
in eight patients and myelodysplasia in six. Logistic
regression was used to analyze the effect of G-CSF
on the rate of complete remission, whereas the log-
rank test and Cox regression analysis were used to
analyze the differences between the two groups with
respect to overall survival, event-free survival, and
disease-free survival. These analyses were done be-
fore and after adjustment for age, risk category, and
transplantation status during a first complete re-
mission (as a time-dependent covariate). Compet-
ing risk analysis was used to calculate the cumula-
tive competing risks of treatment failure among
patients with a complete response (defined as re-
lapse after a complete remission and death during
a first complete remission).
The rates of hematologic recovery after cycles 1
and 2 were analyzed actuarially and compared with
the use of the log-rank test. In these analyses, data
on patients were censored at death or at the start of
the next treatment, if hematologic recovery had not
yet occurred. All P values reported are two-tailed.
 
characteristics of the patients 
and adherence to g-csf treatment
 
Between March 1995 and January 1999, 319 patients
were assigned to induction chemotherapy without
G-CSF, and 321 patients were assigned to chemo-
therapy combined with G-CSF. As of the time of the
data analysis, the median follow-up was 55 months,
and 90 percent of the patients had been followed for
more than 40 months. Thirteen patients were lost to
follow-up or were last seen more than one year be-
fore the analysis. Of these 13 patients, 7 had been
followed for more than three years.
The two treatment groups were evenly matched
with respect to various factors, including assign-
ment to postinduction therapy (Table 1). As for the
prognostic risk groups, most patients were in the
standard-risk category, and approximately 20 per-
cent were in the unfavorable-risk category (Table 1).
Only about 7 percent of all the patients presented
with prognostically favorable AML.
In cycle 1, G-CSF was not given to 16 of the 321
patients who were assigned to receive G-CSF; treat-
ment with G-CSF was delayed (median period, four
days) in 120 of the patients and interrupted (median
period, two days) in 30 patients. The primary reason
for these deviations was leukocytosis (in 75 percent
of cases), as prespecified in the protocol. Other rea-
sons, based on decisions by local physicians, were
usually related to medical problems (e.g., infections,
hemorrhage, liver-function abnormalities, and ur-
ticaria). Of the 279 patients in the G-CSF group who
proceeded to cycle 2, G-CSF was not given to 23 pa-
tients because of leukocytosis, persistent leukemia,
or deviations from the protocol, including 1 patient
because of chemotherapy-associated toxicity dur-
ing cycle 1. In 19 patients treatment with G-CSF
was postponed (median period, one day) because
of leukocytosis or deviations from the protocol.
results
 
* The criteria of the World Health Organization were used to categorize adverse 
effects. The percentages of patients with any grade 3 or 4 side effect or infec-
tion are given. Side effects do not include hair loss. Infections do not include 
fever of unknown origin. The time to hematopoietic recovery was measured 
from the start of chemotherapy. G-CSF denotes granulocyte colony-stimulat-
ing factor.
† Recovery was defined by the presence of both a granulocyte count of more 
than 1.0¬10
 
3
 
 per cubic millimeter and a platelet count of more than 100¬10
 
3
 
 
 
per cubic millimeter.
 
Table 3. Incidence of Grade 3 or 4 Side Effects and Hematopoietic Recovery 
after Induction-Therapy Cycles 1 and 2.*
Variable Cycle 1 Cycle 2
 
No G-CSF G-CSF No G-CSF G-CSF
Grade 3 or 4 side effects (%) 43 47 38 41
Grade 3 or 4 infection (%) 35 38 39 41
Hematopoietic recovery
>1.0¬10
 
3
 
 White cells/mm
 
3
 
 
(median no. of days)
26 26 23 24
>0.5¬10
 
3
 
 Granulocytes/mm
 
3
 
 
(median no. of days)
30 30 25 26
>50¬10
 
3
 
 Platelets/mm
 
3
 
 
(median no. of days)
27 27 28 30
>100¬10
 
3
 
 Platelets/mm
 
3
 
 and 
>1.0¬10
 
3
 
 granulocytes/
mm
 
3
 
 (median no. of days)
35 34 37 37
Recovery by day 56 (% of patients)† 88 91 79 84
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response and adverse effects
 
The rates of complete remission were 83 percent in
the group that did not receive G-CSF and 79 percent
in the group that received G-CSF (P=0.24) (Table 2).
In both groups, 73 percent of the complete remis-
sions occurred after cycle 1. The rates of complete
remission in the two groups did not differ signifi-
cantly according to age or risk group. The frequen-
cies of various grade 3 (severe) or grade 4 (very se-
vere) adverse effects (according to World Health
Organization criteria) after cycles 1 and 2 and the
times to hematopoietic recovery after cycles 1 and
2 were similar in the two groups (Table 3). There
were more deaths within 50 days after cycles 1 and
2 among patients who received G-CSF than among
patients who did not receive G-CSF (Table 4).
 
relapse and survival
 
Among patients who had a complete remission, the
disease-free survival rate at four years was higher in
the G-CSF group than in the group that did not re-
ceive G-CSF (42 percent vs. 33 percent; relative risk
of relapse or death, 0.77; 95 percent confidence in-
terval, 0.62 to 0.96; P=0.02) (Table 2 and Fig. 2).
This difference was related to a lower relapse rate in
the G-CSF group (46 percent vs. 54 percent; relative
risk, 0.77; 95 percent confidence interval, 0.61 to
0.99; P=0.04) (Table 2). At four years there were no
statistically significant differences between the two
groups in the rates of overall and event-free survival
(Table 2 and Fig. 2). The unadjusted Cox regression
analysis and an analysis adjusted for age, risk cate-
gory, and presence or absence of subsequent stem-
cell transplantation during a first complete remis-
sion (time-dependent covariates) yielded similar
estimates for the hazard rates associated with treat-
ment results and P values (data not shown).
 
outcome among distinct prognostic 
subgroups
 
Among patients with standard-risk AML (72 percent
of all patients), treatment with G-CSF reduced the
probability of relapse and improved overall, event-
free, and disease-free survival (Fig. 3A and 3B and
Table 2). G-CSF did not, however, significantly
affect overall, event-free, or disease-free survival
among the 135 patients with unfavorable-risk AML
(Fig. 3C and 3D and Table 2). In the 41 patients with
favorable-risk AML, G-CSF priming had no effect.
Incubation of AML cells with G-CSF, GM-CSF, or
interleukin-3 and the cell-cycle–dependent agent
cytarabine increases intracellular levels of the ac-
tive metabolite cytosine arabinoside triphosphate,
incorporation of cytarabine into cellular DNA,
 
5,7
 
and the killing of leukemic blasts and leukemic pro-
genitor cells by the drug.
 
2-11
 
 We evaluated the clin-
ical efficacy of growth-factor priming in patients
with previously untreated AML. G-CSF was given
beginning one day before the start of chemotherapy
of cycles 1 and 2 and continued through the last day
of induction cycles 1 and 2. Among patients who re-
ceived G-CSF and who had a complete remission,
the relapse rate was lower than that among patients
in complete remission who did not receive G-CSF.
Moreover, in the group of patients who had a com-
plete remission, the disease-free survival rate at
four years was 42 percent in the G-CSF group and
33 percent in the group that did not receive G-CSF
(P=0.02). The difference in overall and event-free
discussion
 
* Numbers and causes of deaths were calculated during induction chemothera-
py cycles 1 and 2 and within 50 days afterward. Overall, there were 34 deaths 
during induction in the group that did not receive G-CSF and 55 in the group 
that received G-CSF (P=0.02).
† Death was classified as due to treatment resistance only if there was patholog-
ical documentation of persistent leukemia.
‡ Death from other causes includes cardiac causes (two in the G-CSF group), he-
patic causes (one in the G-CSF group), hemorrhage (two in the no–G-CSF group 
and six in the G-CSF group), pulmonary causes (one in the no–G-CSF group), 
and other causes (one in the no–G-CSF group and two in the G-CSF group).
§ Leukemia-related deaths were not distinguished from treatment-related caus-
es of death during the first eight days of treatment. NA denotes not assessed.
¶Three patients in each group had excessively high white-cell counts at diagnosis 
 
(>170¬10
 
3
 
 per cubic millimeter; range, 182¬10
 
3
 
 to 344¬10
 
3
 
 per cubic millimeter).
 
Table 4. Mortality Rates Associated with Induction Chemotherapy
with Granulocyte Colony-Stimulating Factor (G-CSF) and without G-CSF.*
Outcome
No. of
Deaths
Death from
Treatment
Resistance†
Death
from
Infection
Death from
Other
Causes‡
 
no. of patients
 
After cycle 1
 
Early death (day 0–8)§
No G-CSF
G-CSF
7¶
11¶
NA
NA
NA
NA
NA
NA
Day 9–50
No G-CSF
G-CSF
11
19
4
2
3
10
4
7
 
After cycle 2
 
Day 0–50
No G-CSF
G-CSF
16
25
9
13
7
8
0
4
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survival did not reach statistical significance. The
significant difference in disease-free survival prob-
ably resulted from G-CSF–mediated activation of
subpopulations of leukemic cells that were initially
insensitive to cytosine arabinoside. Elimination of
the primed cells may have reduced the frequency of
relapse.
The ability of colony-stimulating factors to acti-
vate AML cells has been directly demonstrated in
vivo: injection of G-CSF or GM-CSF 18 to 72 hours
before the beginning of chemotherapy drives AML
cells into the cell cycle.
 
26,27
 
 This effect is consistent
with the notion that G-CSF receptors, because of
their high binding affinity, require minimal levels
of ligands for activation.
 
28
 
From our data, we cannot determine whether
the sensitization effect was mediated by increasing
the efficacy of cytarabine, idarubicin and amsacrin,
or the combined chemotherapeutic agents we used.
In any case, the efficacy of a chemotherapy regimen
that included cytarabine at doses of 200 mg per
square meter as well as 1000 mg per square meter
was enhanced by the addition of G-CSF priming.
Studies of the dose effect of cytarabine have shown
that doses of 3 g per square meter
 
29,30
 
 were more
effective than doses of 200 or 400 mg per square
meter in preventing relapse but did not result in an
increased rate of remission. Similarly, in this study,
only the duration of remission, not the number of
remissions, changed as the result of G-CSF sensiti-
zation.
We used a dose of 1 g of cytarabine per square
meter in cycle 2. The comparative effect of a dose of
1 g per square meter and a dose of 3 g per square
meter has not been established in AML therapy. It
would be of interest to know whether G-CSF prim-
ing would have a similarly positive effect on the
probability of relapse in regimens containing a
dose of 3 g of cytarabine per square meter.
The fact that our results do not suggest a benefit
of G-CSF priming in patients with favorable-risk
AML might relate to the small numbers of cases, or
it might indicate that the dose of 1 g of cytarabine
per square meter was optimal in terms of its ability
to kill neoplastic cells in this subgroup. After the
two induction cycles with or without G-CSF, approx-
imately one third of patients received a third cycle of
chemotherapy and another third went on to high-
dose chemotherapy followed by stem-cell trans-
plantation. It is unlikely that the postinduction treat-
ment influenced the outcome of G-CSF treatment.
The two groups were evenly matched in terms of as-
signment to postinduction therapy. Besides, Cox re-
gression analysis with autologous and allogeneic
transplantation during a first remission as time-
dependent covariates yielded results similar to those
of the unadjusted analysis.
The fact that more deaths occurred during induc-
tion among patients who received G-CSF may ex-
plain the slightly reduced rate of complete remission
in this group. These deaths had several causes and
were thus not due to a common problem. Howev-
er, because of a reduction in the incidence of later
deaths, the overall death rate among patients in the
G-CSF group was lower than that among those
treated with chemotherapy alone.
 
Figure 2. Cumulative Rate of Overall Survival (Panel A) and Disease-free 
Survival (Panel B), According to the Assigned Treatment.
 
P values were calculated with use of the log-rank test. G-CSF denotes granulo-
cyte colony-stimulating factor.
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Previous studies of G-CSF and GM-CSF in AML
have been almost entirely confined to the ability of
these growth factors to accelerate hematopoietic re-
covery and reduce morbidity and mortality due to in-
fection after chemotherapy. The efficacy of these
agents in modulating chemotherapy has, howev-
er, been evaluated in controlled
 
18-21
 
 and uncon-
trolled
 
15-17
 
 studies involving limited numbers of pa-
tients. In two relatively large, randomized studies,
GM-CSF was administered concomitantly with and
after chemotherapy.
 
31,32
 
 These studies involved old-
er patients, most of whom had AML with an unfa-
vorable prognosis. One of these studies reported a
higher rate of disease-free survival among the pa-
tients who received GM-CSF than among those who
did not receive GM-CSF,
 
32
 
 but it was not possible to
distinguish the effect of priming from the effect of
enhanced hematopoietic recovery. By contrast, our
study selectively focused on the effect of growth-
factor priming in AML and was conducted in young
and middle-aged adults with previously untreated
leukemia.
We found that G-CSF improved overall and dis-
ease-free survival in the group with standard-risk
AML. There were too few patients in the group with
a favorable prognosis to allow a meaningful analy-
sis. There was no indication that G-CSF priming im-
proved the outcome among patients with chemo-
therapy-refractory, unfavorable-risk AML. This lack
of benefit explains why overall survival was not sig-
nificantly better in the G-CSF group as a whole.
Additional studies of G-CSF priming in specific
subgroups of patients and regimens of combination
therapy seem warranted. The results of our study
provide proof of the principle that chemotherapy
and sensitization of leukemia cells by hematopoietic
growth factors is a plausible strategy for reducing
the risk of relapse in patients with AML.
 
Figure 3. Cumulative Rates of Overall Survival (Panels A and C) and Disease-free Survival (Panels B and D) among Patients with Standard-
Risk Acute Myeloid Leukemia (AML) and Unfavorable-Risk AML.
 
P values were calculated with use of the log-rank test. G-CSF denote granulocyte colony-stimulating factor.
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